Contact this trialFirst, we need to learn more about you.
Biological DMARD
Certolizumab for Rheumatoid Arthritis
Recruiting1 award5 criteria
Boston, Massachusetts
This trial is studying how well inflammation and lipoprotein atherogenicity (a measure of how likely a fat molecule is to cause problems in arteries) work together to predict cardiovascular risk in people with rheumatoid arthritis.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.